192 related articles for article (PubMed ID: 9332325)
1. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
Shipman CM; Rogers MJ; Apperley JF; Russell RG; Croucher PI
Br J Haematol; 1997 Sep; 98(3):665-72. PubMed ID: 9332325
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates induce apoptosis in human breast cancer cell lines.
Senaratne SG; Pirianov G; Mansi JL; Arnett TR; Colston KW
Br J Cancer; 2000 Apr; 82(8):1459-68. PubMed ID: 10780527
[TBL] [Abstract][Full Text] [Related]
3. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Aparicio A; Gardner A; Tu Y; Savage A; Berenson J; Lichtenstein A
Leukemia; 1998 Feb; 12(2):220-9. PubMed ID: 9519785
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate therapy in multiple myeloma: past, present, future.
Jantunen E
Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
[TBL] [Abstract][Full Text] [Related]
7. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.
Sonnemann J; Eckervogt V; Truckenbrod B; Boos J; Winkelmann W; van Valen F
Anticancer Drugs; 2001 Jun; 12(5):459-65. PubMed ID: 11395574
[TBL] [Abstract][Full Text] [Related]
8. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
Takahashi R; Shimazaki C; Inaba T; Okano A; Hatsuse M; Okamoto A; Hirai H; Ashihara E; Nakagawa M
Leuk Res; 2001 Jan; 25(1):77-83. PubMed ID: 11137564
[TBL] [Abstract][Full Text] [Related]
9. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates induce breast cancer cell death in vitro.
Fromigue O; Lagneaux L; Body JJ
J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines.
Nishida S; Kikuichi S; Haga H; Yoshioka S; Tsubaki M; Fujii K; Irimajiri K
Biol Pharm Bull; 2003 Jan; 26(1):96-100. PubMed ID: 12520182
[TBL] [Abstract][Full Text] [Related]
12. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Shipman CM; Vanderkerken K; Rogers MJ; Lippitt JM; Asosingh K; Hughes DE; Van Camp B; Russell RG; Croucher PI
Br J Haematol; 2000 Oct; 111(1):283-6. PubMed ID: 11091214
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates--mechanisms of action in multiple myeloma.
Shipman CM; Rogers MJ; Vanderkerken K; Van Camp B; Graham R; Russell G; Croucher PI
Acta Oncol; 2000; 39(7):829-35. PubMed ID: 11145441
[TBL] [Abstract][Full Text] [Related]
14. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
[TBL] [Abstract][Full Text] [Related]
15. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.
Iguchi T; Miyakawa Y; Yamamoto K; Kizaki M; Ikeda Y
Cell Signal; 2003 Jul; 15(7):719-27. PubMed ID: 12742232
[TBL] [Abstract][Full Text] [Related]
16. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.
Forsea AM; Müller C; Riebeling C; Orfanos CE; Geilen CC
Br J Cancer; 2004 Aug; 91(4):803-10. PubMed ID: 15280922
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour activity of bisphosphonates in human myeloma cells.
Shipman CM; Rogers MJ; Apperley JF; Graham R; Russell G; Croucher PI
Leuk Lymphoma; 1998 Dec; 32(1-2):129-38. PubMed ID: 10037008
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
Walter C; Pabst A; Ziebart T; Klein M; Al-Nawas B
Oral Dis; 2011 Mar; 17(2):194-9. PubMed ID: 20796232
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.
Mönkkönen J; Taskinen M; Auriola SO; Urtti A
J Drug Target; 1994; 2(4):299-308. PubMed ID: 7858955
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Cheng YY; Huang L; Lee KM; Xu JK; Zheng MH; Kumta SM
Calcif Tissue Int; 2004 Jul; 75(1):71-7. PubMed ID: 15037971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
